Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Compositions and Methods for Identifying and Modulating Metabolic Health

a metabolic health and composition technology, applied in the field of compositions and methods for identifying and modulating metabolic health, can solve problems such as hypervascularization in many tissues

Inactive Publication Date: 2018-03-08
DUKE UNIV
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present patent provides methods for identifying and treating metabolic dysfunction in subjects. The methods are based on changes in the ratio of visceral adipose tissue (VAT) to subcutaneous adipose tissue (SAT) and the prevalence of hypertrophic and hyperplastic adipocyte morphology. The methods can be used in subjects with or at risk for metabolic dysfunction, including insulin resistance, hyperlipidemia, hypertension, and fatty liver. The methods may involve decreasing or increasing the level or activity of certain genes or proteins. The patent also provides methods for predicting metabolic dysfunction based on changes in biomarkers. Overall, the patent provides new ways to identify and treat metabolic dysfunction in subjects.

Problems solved by technology

Mutation of Plxnd1 in mouse and zebrafish leads to hypervascularization in many tissues.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and Methods for Identifying and Modulating Metabolic Health
  • Compositions and Methods for Identifying and Modulating Metabolic Health
  • Compositions and Methods for Identifying and Modulating Metabolic Health

Examples

Experimental program
Comparison scheme
Effect test

example 1

Methods of Zebrafish plxnd1 Engineering and Analysis

[0106]Zebrafish husbandry and staging. To test the role of Plxnd1 in body fat distribution, Zebrafish were genetically engineered to disrupt the function of the Plxnd1 gene according to methods known to the art, described in the present disclosure, as well as methods and references incorporated herein. Zebrafish were raised, fed, and housed as described. (Westerfield M (2000) The Zebrafish Book-A guide for the laboratory use of zebrafish (Danio rerio). University of Oregon Press, Eugene, Oreg.; Flynn E J, et al. (2009), Journal of lipid research 50 (8):1641-1652; Imrie D & Sadler K C (2010), Developmental dynamics. 239 (11):3013-3023.) The plxnd1fov01b null mutation was maintained on transgenic Tg(fli1a:egfp)y1 (hereafter referred to as fli1a:EGFP) or Tg(kdrl:HsHRAS-mCherry)s896 (hereafter referred to as flk1:mcherry) on Ekkwill backgrounds. (Torres-Vazquez J, et al. (2004), Developmental cell 7 (1):117-123; Childs S, et al. (2002)...

example 2

PLXND1mRNA is Positively Associated with Hypertrophic Morphology in Human VAT, but not SAT

[0116]Human gene expression and morphology methods. Subjects were investigated in the morning after an overnight fast. To relate PLXND1 expression to AT morphology (FIG. 1F), VAT and SAT biopsies were taken from 79 obese women scheduled for gastric bypass surgery. Morphology in each adipose depot (hyperplastic / hypertrophic) was determined as described. (Hoffstedt J, et al. (2010), Diabetologia 53 (12):2496-2503.) Neither morphology, nor hypertrophic AT were dependent on BMI. mRNA was quantified in AT as described. (Ryden M, et al. (2007), American journal of physiology. Endocrinology and metabolism 292 (6):E1847-1855.) qRT-PCR was performed using pre-TaqMan kits for PLXND1 (HS 00391129_m1), and LRP10 (Hs01047362_m1) (Applied Biosystems). Expression of PLXND1 was normalized to the LRP10 internal control using the comparative Ct method. PLXND1 mRNA expression was found to be slightly higher in SA...

example 3

ECM Dynamics in PLXND1Mutant Zebrafish

[0118]Col5a1 is induced by vascular endothelial cells of plxnd1 mutant zebrafish VAT

[0119]qRT-PCR revealed large-scale dysregulation of ECM components within plxnd1 mutant VAT (FIG. 2A; see also Table 1 for qRT-PCR primers). A subset of ECM components were downregulated (FIG. 2A); however, the type V collagens col5a1and col5a3b were increased (FIG. 2A).

[0120]Immunofluorescence confirms an increase in Col5 protein and reveals specific localization to vascular endothelial cells in plxnd1 mutant VAT (FIGS. 2B& C). FACS enrichment of endothelial cells followed by qRT-PCR shows that col5a1 mRNA is increased in plxnd1 mutant endothelial cells (FIG. 2D), supporting a vascular endothelial cell origin for Col5a1 in plxnd1 mutant VAT.

[0121]Knockdown of Col5a1 normalizes hyperproliferation and hyperplastic morphology within plxnd1 mutant VAT

[0122]Zebrafish col5a1 was targeted with multiple, non-overlapping Vivo-Morpholinos (vMOs) (FIG. 9).

[0123]Zebrafish w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
diameteraaaaaaaaaa
concentrationaaaaaaaaaa
Login to View More

Abstract

This invention provides reagents, methods and biochemical markers for identifying and providing therapeutic intervention for individuals with metabolic dysfunction, or individuals at risk for metabolic dysfunction.

Description

BACKGROUND OF THE INVENTIONField of the Invention[0001]This disclosure provides reagents, methods and biochemical markers for identifying and treating individuals with metabolic dysfunction, and for determining efficacy of a therapeutic intervention to correct metabolic dysfunction. Specifically, embodiments of the present disclosure relate to novel methods of identifying and treating metabolic disease mediated by PLEXIN D1 (PLXND1) and COLLAGEN 5A1 (COL5A1), wherein the distribution and morphology of adipose tissue (AT) is disrupted relative to normal, healthy individuals.Description of Related ArtAdipose Tissue Distribution and Morphology[0002]The regional distribution and morphology of AT are strong predictors of metabolic disease (Salans L B, Knittle J L, & Hirsch J (1968), The Journal of clinical investigation 47 (1):153-165; Ahima R S & Lazar M A (2013), Science 341 (6148):856-858; Amer E & Amer P (2013), Science 342 (6158):558-559.) Excess lipid deposition in visceral adipose...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68A61K45/06A61K38/26A61K38/28A61K39/395
CPCG01N33/6893A61K45/06A61K38/26A61K38/28A61K39/39541G01N2800/042A61P3/00
Inventor RAWLS, JOHN F.MINCHIN, JAMES
Owner DUKE UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com